CLGN · CollPlant Biotechnologies Ltd.

Summary

CollPlant Biotechnologies reported 2025 financial results with GAAP revenues of $2.4 million, up from $515,000 in 2024 due to a $2 million AbbVie milestone payment, and a reduced GAAP net loss of $11.5 million or $0.94 per share versus $16.6 million or $1.45 per share prior year. The company highlighted pipeline progress, including rhCollagen bioprinting launches, breast implant preclinical data, and new patents, alongside cost reductions and a $3.1 million financing.

Key takeaways

• GAAP revenues $2.4 million for year ended Dec 31, 2025 vs $515,000 in 2024
• GAAP net loss $11.5 million or $0.94 per share in 2025 vs $16.6 million or $1.45 per share in 2024
• Received $2 million milestone payment from AbbVie in Feb 2025
• Cash and equivalents $5.6 million as of Dec 31, 2025
• Registered direct offering in June 2025 raised $3.1 million net proceeds
• Workforce reduced by 25% in Nov 2025 cost reduction plan